Metastatic breast cancer: The role of pegylated liposomal doxorubicin after conventional anthracyclines

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), 2005, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, 365, 1687, 10.1016/S0140-6736(05)66544-0 Swain, 2003, Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials, Cancer, 97, 2869, 10.1002/cncr.11407 Seidman, 2002, Cardiac dysfunction in the trastuzumab clinical trials experience, J Clin Oncol, 20, 1215, 10.1200/JCO.20.5.1215 Bria E, Cuppone F, Fornier M, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 2007. <http://www.springerlink.com/content/y746x471737468r8/> [published online 19.07.07]. O’Brien, 2004, Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCL (Caelyx/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer, Ann Oncol, 15, 440, 10.1093/annonc/mdh097 Safra, 2000, Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500mg/m2, Ann Oncol, 11, 1029, 10.1023/A:1008365716693 Batist, 2007, Cardiac safety of liposomal anthracyclines, Cardiovasc Toxicol, 7, 72, 10.1007/s12012-007-0014-4 O’Shaughnessy, 2003, Pegylated liposomal doxorubicin in the treatment of breast cancer, Clin Breast Cancer, 4, 318, 10.3816/CBC.2003.n.037 Rivera, 2003, Liposomal anthracyclines in metastatic breast cancer: clinical update, Oncologist, 8, 3, 10.1634/theoncologist.8-suppl_2-3 Lorusso, 2007, Role of liposomal anthracyclines in breast cancer, Ann Oncol, 18, vi70, 10.1093/annonc/mdm229 Ranson, 1997, Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial, J Clin Oncol, 15, 3185, 10.1200/JCO.1997.15.10.3185 Lyass, 2000, Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma, Cancer, 89, 1037, 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z Schmid, 2004, Biweekly pegylated liposomal doxorubicin (Caelyx/Doxil) in heavily pretreated patients with metastatic breast cancer, Breast Cancer Res Treat, 81, 5059 Mlineritsch, 2004, Phase II study of single-agent pegylated liposomal doxorubicin HCl (PLD) in metastatic breast cancer after first-line treatment failure, Onkologie, 27, 441, 10.1159/000080363 Al-Batran, 2006, The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial, Br J Cancer, 94, 1615, 10.1038/sj.bjc.6603158 Al-Batran, 2006, Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer, Oncology, 70, 141, 10.1159/000093005 Coleman, 2006, A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993), Eur J Cancer, 42, 882, 10.1016/j.ejca.2005.12.011 Yardley DA, Shipley DM, Greco FA, et al. Phase II randomized trial of pegylated liposomal doxorubicin vs. weekly docetaxel with subsequent crossover as first-line chemotherapy for metastatic breast cancer. In: Presented at the San Antonio breast cancer symposium; 2004 [Poster 5057]. Keller, 2004, Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer, J Clin Oncol, 22, 3893, 10.1200/JCO.2004.08.157 Alba E, Ruiz-Borrego M, Martin M, et al. Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomized trial following standard chemotherapy for MBC: GEICAM 2001-01 study. J Clin Oncol 2007;25(18s):1007 [abstract updated from slides]. Overmoyer, 2005, Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer, Clin Cancer, 6, 150 Vandenberg TA, Trudeau M, Provencher L, et al. Pegylated liposomal doxorubicin (PLD) with cyclophosphamide (C) as 1st-line chemotherapy for metastatic breast cancer (MBC) patients previously treated with adjuvant anthracyclines. J Clin Oncol 2006;24(18S):10627 [abstract]. Dufour PR, Rousseau F, Meyer N, et al. Phase II trial of pegylated liposomal doxorubicin-cyclophosphamide combination as first-line chemotherapy in elderly metastatic breast cancer patients. J Clin Oncol 2007;25(18S):19565 [abstract]. Rigatos, 2003, Paclitaxel and liposomal doxorubicin (Caelyx) combination in advanced breast cancer patients: a phase II study, Oncology Reports, 10, 1817 Siomoncini E, Ferrari VD, Amoroso V, et al. Bi-weekly administration of pegylated liposomal doxorubicin plus paclitaxel in metastatic breast cancer (MBC) patients: a phase II study. J Clin Oncol 2005;23(16S):844 (abstract). Vorobiof, 2004, First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study, The Breast, 13, 219, 10.1016/j.breast.2004.01.006 Alexopoulos, 2004, Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer, Ann Oncol, 15, 891, 10.1093/annonc/mdh218 Guastalla JP, Largillier R, Geay JF, et al. Docetaxel (Do) and liposomal pegylated doxorubicin in metastatic breast cancer (MBC) patients (pts): The French GINECO group experience. J Clin Oncol 2006;24(18S):10589 [abstract]. Holmes, 2003, Phase II study of weekly pegylated liposomal doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer, Breast Cancer Res Treat, 82, 537 Morabito, 2004, Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer, Breast Cancer Res Treat, 86, 249, 10.1023/B:BREA.0000036898.45123.e9 Martin, 2004, Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure, Clin Breast Cancer, 5, 353, 10.3816/CBC.2004.n.041 Chow, 2007, A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer, Am J Clin Oncol, 30, 133, 10.1097/01.coc.0000251400.47711.fe Ardavanis, 2006, Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study, Cancer Chemother Pharmacol, 58, 742, 10.1007/s00280-006-0236-3 Gebbia, 2002, Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma, Oncology, 63, 23, 10.1159/000065716 Rivera, 2003, Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer, J Clin Oncol, 21, 3249, 10.1200/JCO.2003.03.111 Fabi, 2006, Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naive and anthracycline pretreated metastatic breast cancer patients, Cancer Chemother Pharmacol, 57, 615, 10.1007/s00280-005-0116-2 Chia, 2006, Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial, J Clin Oncol, 24, 2773, 10.1200/JCO.2005.03.8331 Wolff, 2004, Breast Cancer Res Treat, 88, S125 Gennari, 2006, Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer, J Clin Oncol, 24, 3912, 10.1200/JCO.2006.06.1812 Cianfrocca ME, Rosen ST, von Roenn JH, et al. A phase I trial of pegylated liposomal anthracycline and lapatinib (L) combination in the treatment of metastatic breast cancer (MBC): first evaluation of an anthracycline and lapatinib combination in the treatment of MBC. J Clin Oncol 2007;25(18S):1079 [abstract]. Chuang E, Vahdat L, Caputo T, et al. Phase I clinical trial of ixabepilone and pegylated liposomal doxorubicin in patients with advanced breast or ovarian cancers: New York Cancer Consortium Trial P7729. J Clin Oncol 2007;25(18S):2570 [abstract]. Trudeau M, Madarnas Y, McCready D, Pritchard KI, Messersmith H, The Breast Cancer Disease Site Group. The role of trastuzumab in adjuvant and neoadjuvant therapy in women with HER2/neu-overexpressing breast cancer: a clinical practice guideline. Program in evidence-based care, a cancer Ontario program; 2006. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: breast cancer – Version 2.2007. Available from: <www.nccn.org> 2007. Dahabreh, 2007, Trastuzumab with adjuvant chemotherapy for resectable breast cancer: a meta-analysis, Ann Oncol, 18, 29P Smith, 2007, 2-Year follow-up of trastuzumab after adjuvant chemotherapy for HER2-positive breast cancer: a randomized controlled trial, Lancet, 369, 29, 10.1016/S0140-6736(07)60028-2 Romond, 2005, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, 353, 1673, 10.1056/NEJMoa052122 Tan-Chiu, 2005, J Clin Oncol, 23, 7811, 10.1200/JCO.2005.02.4091 Slamon, 2006, Br Cancer Treat Res Paik, 1998, erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer, J Natl Cancer Inst, 90, 1361, 10.1093/jnci/90.18.1361 Paik, 2000, HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15, J Natl Cancer Inst, 92, 1991, 10.1093/jnci/92.24.1991 Pritchard, 2006, HER2 and responsiveness of breast cancer to adjuvant chemotherapy, N Engl J Med, 354, 2103, 10.1056/NEJMoa054504 Andreopoulou, 2007, Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer, Clin Breast Cancer, 7, 690, 10.3816/CBC.2007.n.028 Wilkes, 2005, Palmar-plantar erythrodysesthesia, Clin J Oncol Nurs, 9, 103, 10.1188/05.CJON.103-106 Grenier N, Lebel V, Gill M, et al. Nursing support program to decrease or prevent side effects of pegylated liposomal doxorubicin (PLD) in patients with recurrent epithelial ovarian cancer (REOC). J Clin Oncol 2005;23(16S):8198 [Part I of II (June 1 Suppl.), abstract]. Coates, 2003, Controversies in metastatic breast cancer: optimal duration of chemotherapy, Am Soc Clin Oncol Ed Book, 119